Summary.-Tumour metastasis in BCG-pretreated mice was studied using a methylcholanthrene-induced fibrosarcoma in C3H/He mice. When tumour cells were injected into the BCG-primed site, distant metastasis occurred in the lungs and the popliteal lymph node, though this tumour did not metastasize in normal mice. Such metastases were increased in proportion to the number of tumour cells injected into the BCG-primed site, and developed soon after tumour challenge. Concomitant immunity developed well in the mice bearing such metastases, but did not inhibit metastatic growth. Experiments using 1251-labelled SRBC or tumour cells revealed that such cells egressed rapidly from the BCG-primed site. When the tumour was inoculated into the contralateral foot to the BCG-primed site, the incidence and the number of metastases was reduced. Furthermore, BCG infection induced an increase of platelet count. I.v. injection of this tumour induced marked thrombocytopenia in normal mice. Administration of pentoxifylline, a methylxanthine derivative, before tumour challenge reduced such metastases. These findings suggest that the changes in peripheral blood, such as increased platelet count and increased release of tumour cells from the injection site, facilitated distant metastasis in BCG-pretreated mice.
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WE HAVE PREVIOUSLY REPORTED that a high dose of MCA-induced fibrosarcoma injected at a BCG-primed site induced distant metastases in the draining lymph node and the lungs, whereas this same tumour did not metastasize in normal mice (Ishibashi et al., 1978a) . The mechanisms responsible for this tumour spread in BCG-primed mice are not known. However it was also found previously that the direct plaque-forming cells (PFC) were produced in various widely distributed lymphoid organs such as spleen and axillary lymph node, when sheep red blood cells were injected into the BCG-primed foot pad, whereas in normal mice the direct PFC were mainly found in the draining popliteal lymph node after SRBC injection into the hind foot pad. (Ishibashi et al., 1 978b) . These findings suggested that the inflammatory changes produced by BCG infection would facilitate the migration of foreign bodies such as SRBC to the distant organs. The purpose of the present paper is to report the facilitation of migration of tumour cells injected into the BCGprimed site and the development of metastasis, and to analyse the mechanisms of the promotion of such metastasis.
MATERIALS AND METHODS
Animals.-Male and female C3H/He mice were used throughout the experiments. They were obtained from the animal supply centre in Kyushu University. Animals were 8 weeks old at the beginning of the experiments. In each experiment, mice of same age and sex were divided into 2 groups. One group of mice was injected with BCG and the other group without BCG injection served as contemporaneous controls.
BCG.-Lyophilized BCG, Strain Japan, was obtained from the Japan BCG Laboratory T. ISHIBASHI El' AL.
(Tokyo, Japan). One mg of BCG was injected into the hind foot pad in a volume of 0 05 ml of saline.
Tumour and tumour transplantation.-A previously described MCA-induced fibrosarcoma was used throughout the experiments. The tumour-cell suspension was prepared according to the method described previously (Ishibashi et al., 1978a Louis, Mo., Type VII) 5 mg of glucose, 0-1 mg of lactoperoxidase (P-L Biochemicals, Inc., Milwaukee, Wis.) and 0-2 mCi of carrier-free Na 125J (New England Nuclear Corp., Boston, Mass.). Incubation was carried out for 20 min at 37°C with constant agitation. Thereafter the cells were rinsed 7 x in cold phosphate-buffered saline. Schenkein et al. (1972) noted that this method produced a marked increase in the incorporation of radioactivity in the cell surface, and a significant improvement of cell survival. primed foot pad was significantly more rapid than that seen in normal foot pad tases developed at the times examined. On the other hand ing excision of the uptake of labelled SRBC in the drainter tumour chal-ing popliteal node of BCG-pretreated mice gress of tumour increased significantly faster than that occurred imme-seen in controls at any time. Moreover culation at the the peak uptake of labelled SRBC in the popliteal node was seen at 3 h in BCGr'-labelle SRBC pretreated mice, whereas it reached a -labelled SRBO peak at 24 h in controls. The uptake of ed site labelled SRBC in distant organs such as in showed that inguinal lymph node, spleen and lungs, in a was composed BCG-pretreated mice was higher than that ges resembling in controls at 3 h, although the differences *tes were inter-between both groups were not significant. ophage clusters was increased Organ distribution of 125k labelled tumour These findings cells injected into the BCG-primed site ies injected into Mice were injected with 2-5 x 105 1251-.ly migrate from labelled tumour cells into the right hind Group 1 mice (A) were injected with 1 mg of BCG into the right hind foot pad. 7 weeks later, mice of Group 1 and 2 (0) were injected with 5 x 104 tumour cells into the right hind foot pad and 2 weeks later the tumour sites were excised. Group 3 mice (0) served as normal controls. All mice were challenged with 2 x 105 tumour cells into the back one week after tumour excision. No. of mice with tumour developed/total mice in each group was: Group 1, 3/6; Group 2, 6/7; Group 3, 6/6. tumour site of both groups were amputated. Group 3 mice without treatment served as normal controls. All mice were concurrently injected with 2 x 105 tumour cells into the centre of the back one week after tumour excision. The results in the Figure show that tumour growth was strongly suppressed in both immunized groups as compared to controls. The differences between both immunized groups and control group were significant to P <0(001 at the times examined. The suppression of tumour growth in mice immunized with tumour at the BCGprimed site was greater than that in the mice immunized with tumour only, but the difference was not significant.
The next experiment was performed to determine whether the primary growing tumour affected the immunity to rechallenged tumour. Mice were divided into 5 groups. Groups 1 and 2 were inoculated with 1 mg of BCG into the right hind foot pad. Group 3 and 4 served as tumour control without BCG pretreatment. Seven weeks after BCG injection, mice of Groups 1 to 4 were injected with 105 tumour cells, as a high tumour dose, into the right hind foot pad (BCG-primed site). Group 5 received no pretreatment as normal controls. Two weeks after tumour inoculation. the primary tumour of Groups 2 and 4 was excised. All mice were rechallenged with 2 x 105 tumour cells in the back one week after excision of the primary tumour. Mice were killed 2 weeks after tumour rechallenge and the metastases examined. The results are summarized in Table VII . Rejection and growth of rechallenging tumours of the mice bearing primary tumour at the BCG-primed site (Group 1) was similar to that in the mice undergoing excision of primary tumour at the BCG site (Group 2). However, immunity to rechallenging tumour in the mice bearing primary growing tumour without BCG pretreatment (Group 3) was slightly lower than in mice undergoing excision of primary tumour (Group 4). In contrast, distant metastases in the draining node and lungs were observed only in mice Table VIII . The RBC count and the platelet count increased after BCG infection. The significance of the differences between the RBC count of normal control mice and those of BCG infected mice was P < 0 001 and P < 0 01 respectively, 4 and 8 weeks after BCG infection. The platelet count showed a significant increase 12 weeks after BCG infection (P < 0.05). There are no significant changes in the WBC count. Although the data were not shown, differential cell counts with Giemsa-stained blood smears showed an increasing ratio of mononuclear cells to PMN with time after BCG infection.
Effect of pentoxifylline on metastasis
First the platelet count was made after i.v. injection of 2 x 105 tumour cells into normal mice. The platelet count decreased to 60% of controls at 30 min and 42% at 3 h after tumour inoculation. The methylxanthine derivative, pentoxifylline (Trental, Hoechst, Germany), is shown to improve the deformability of red blood cells and decrease blood viscosity. (Muller et al., 1975; Ehrly, 1976) . Furthermore, Gastpar (1974) noted that it inhibited platelet adhesion and aggregation to circulating sticky tumour cells, and their attachment to the endothelium, and blocked subsequent thrombus formation. The next experiment was performed to (Miller et al., 1973; Ishibashi et at., 1977a) . Furthermore, several investigators reported that direct contact between BCG and tumour cells was necessary to inhibit tumour growth (Bartlett et al., 1972; Baldwin & Pimm, 1973) . We therefore supposed that suppression of tumour growth would be obtained when tumour cells were inoculated into the BCG-primed site. However, we found that distant metastases in the lungs and the draining lymph node occurred unexpectedly, when a high tumour dose was injected into the BCG-primed site, whereas a low dose of tumour cells did not grow (Ishibashi et al., 1978a) . The mechanisms of the promotion of distant metastasis in our experimental system could be classified as local or systemic (specific or nonspecific). We thought that the increased egress of tumour cells from the BCG-primed site would be important as a local factor, since Fidler (1973a) reported that the number of lung metastases was proportional to the number of viable cells injected i.v. Moreover, Courtade et al. (1975) noted that capillary density increased in BCG lesions in rabbits. Our previous studies revealed that direct plaque-forming cells were produced in distant lymphoid organs when SRBC were injected into the BCG-primed site (Ishibashi et al., 1978b into the contralateral foot pad in BCGpretreated mice, the incidence and the number of metastases in the lungs was less than when the tumour was injected into the BCG-primed site. It seemed that both the increased release of tumour cells from the site of injection, and some systemic effect of BCG infection, were important for the development of distant metastasis, which did not occur in normal mice. When tumour cells were injected i.v. at a distance from the BCG-primed site, there was a significant inhibition of pulmonary metastasis following a low dose of tumour inoculum. These data are consistent with the previous results showing a slight inhibition of tumour growth after inoculation of a low tumour dose in the contralateral foot pad (Ishibashi et al., 1978a) . However, it was of interest that, in the case of a high tumour dose, there was slight promotion of pulmonary metastasis in BCG-pretreated mice. These results suggested that the inhibitory effect of BCG pretreatment on tumour growth, whether specific or nonspecific, could not operate when the dose of tumour inoculum exceeded some threshold. On the contrary, some systemic nonspecific effect of BCG infection might even promote tumour growth in such a case. We observed, however, that even in normal mice radiolabelled tumour cells injected into the foot pad egressed and entered distant organs. These results agreed with the report by Fisher & Fisher (1967) that s.c. inoculation of Walker tumour cells into the legs was followed by a rapid egress of cells from the injection site to other organs. Nevertheless, in our system distant metastases were never seen in normal mice. We consider that the systemic effect of BCG infection on specific tumour immunity might promote distant metastasis. It was supposed that BCG might alter the host's immune response to a tumour by the production of blocking factors, since we previously observed that BCG initially stimulated cell-mediated immunity, but later enhanced antibody formation (Ishibashi et al., 1977a, b) . The results in Table VII show that strong tumour immunity developed in the BCG-pretreated mice with or without excision of the primary tumour, whereas distant metastasis occurred similarly in both groups of BCG-pretreated mice. It was therefore concluded that tumour cells were arrested in the distant organs such as lungs immediately after tumour challenge and grew to metastases before tumour immunity developed or while it was yet weak, since several investigators noted that a weak incipient immune response stimulated rather than inhibited tumour growth (Prehn, 1972; Fidler, 1974) . In general, the development of tumour metastasis was thought to be influenced by many factors, such as tumour-cell properties (Fidler, 1 973b; Nicolson & Winkelhake, 1975) host immune response (Baldwin & Pimm, 1973; Fidler, 1974) platelet level (Gasic etal., 1968 (Gasic etal., , 1973 fibrin formation (Wood, 1958) endothelial injury in the capillary bed (Fidler & Zeidman, 1972) and tumour immunogeinicity (Fidler et al., 1979) etc. Subsequently we considered that some systemic nonspecific effect of BCG might promote distant metastasis. It is assumed that more tumour cells are trapped due to the change in capillary bed produced by BCG-granuloma, because BCG infection sometimes causes granuloma production in the lungs. But histological examination revealed no granuloma around the metastatic foci in the lungs. Gordon et al. (1977) noted that BCG administered to irradiated mice increased the numbers of haemopoietic precursor cells in the marrow and spleen. It seems likely from their findings that BCG might increase the production of megakaryocytes and the platelet level might then increase in BCGpretreated mice which would facilitate pulmonary metastasis. The results in Table VIII showed that BCG infection induced a significant increase in platelet count. Gasic et al. (1973) noted that many tumours produced thrombocytopenia in vivo, which was most active against metastases produced by tumours with the capacity to aggregate platelets. The tumour used in the present experiments also produced thrombocytopenia. Therefore, the reduction of distant metastases by pentoxifylline implied peripheral-blood changes such as the increased platelet count in BCG-infected mice, which induced distant metastasis and inhibited the expression of specific tumour immunity.
